Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biotechnology company based in Berkeley Heights, New Jersey, has made significant strides in treating fibromyalgia with its newly launched medication, TONMYA (cyclobenzaprine HCl sublingual tablets). Launched in the U.S. In November 2025, TONMYA is the first FDA-approved treatment for fibromyalgia in adults in over 15 years, marking a pivotal moment for patients seeking long-term relief from this chronic condition.
TONMYA offers a novel approach for managing fibromyalgia, utilizing a unique sublingual formulation that promotes rapid absorption and effectively bypasses first-pass liver metabolism. This design aims to enhance the durability of treatment effects, addressing a critical need for patients who often experience only transient relief from existing oral medications. According to Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, the proprietary basifying agent in TONMYA’s formulation plays a crucial role in achieving these benefits.
Recent research findings published in the peer-reviewed journal Clinical Pharmacology in Drug Development highlight the pharmacokinetic advantages of TONMYA, which include enhanced absorption rates and reduced production of the active metabolite norcyclobenzaprine. These features contribute to a more effective management of fibromyalgia symptoms compared to traditional oral medications, which generally provide only short-term relief.
Clinical Studies and Results
Tonix Pharmaceuticals conducted two Phase 1 single-dose, open-label studies to evaluate the pharmacokinetics of TONMYA. In the first study, which involved 24 healthy adult volunteers, three different sublingual formulations of cyclobenzaprine HCl were tested against an immediate-release oral formulation. The potassium phosphate dibasic formulation, designated TNX-102 SL, demonstrated a remarkable 154% relative bioavailability compared to its oral counterpart, with a significantly shorter absorption lag of approximately three minutes.
The second study compared two dosages of TNX-102 SL (2.8 mg and 5.6 mg) under both fasting and fed conditions. Notably, the pharmacokinetic parameters remained stable regardless of meal conditions, indicating that food does not affect the absorption of the drug. The study also confirmed that the active metabolite norcyclobenzaprine has an elimination half-life of around 60 hours, further supporting the potential for a sustained therapeutic effect from TONMYA.
Understanding Fibromyalgia
Fibromyalgia is a chronic pain disorder that affects an estimated 6 to 12 million adults in the United States, predominantly women. Those suffering from this condition experience widespread pain, fatigue, nonrestorative sleep, and cognitive dysfunction, often leading to significant impairment in daily activities and quality of life. Current treatment options have been met with mixed reviews, as many patients report inadequate symptom control.
TONMYA is designed to address these challenges by improving the analgesic response and overall tolerability compared to previously available treatments. The innovative formulation aims to provide patients with a more effective and durable solution to manage their symptoms, ultimately enhancing their quality of life.
Safety and Considerations
In terms of safety, the clinical studies reported that all treatment-emergent adverse events were mild to moderate, with common side effects including oral hypoesthesia and an abnormal taste. No serious adverse events were observed, and no clinically significant changes were noted in vital signs or laboratory parameters. However, the company advises caution regarding potential drug interactions, particularly with monoamine oxidase inhibitors (MAOIs) and other serotonergic medications, which could heighten the risk of serotonin syndrome.
TONMYA may not be suitable for certain populations, including those with hypersensitivity to cyclobenzaprine, as well as pregnant or breastfeeding individuals. The company recommends thorough discussions with healthcare providers to assess individual risks and benefits before starting treatment.
Future Outlook
Moving forward, Tonix Pharmaceuticals is optimistic about the potential of TONMYA not just for treating fibromyalgia but also for other conditions, including acute stress reaction and major depressive disorder. The ongoing research and development efforts reflect the company’s commitment to addressing significant unmet medical needs in the areas of central nervous system disorders and immunology.
The approval of TONMYA symbolizes a crucial advancement in the treatment landscape for fibromyalgia, providing renewed hope for millions of individuals battling this challenging condition. As the company continues its research and development initiatives, healthcare professionals and patients alike will be watching closely for further updates on the efficacy and safety of this new therapeutic option.
For those interested in the latest developments in fibromyalgia treatment, Tonix Pharmaceuticals encourages ongoing communication with healthcare providers and staying informed about emerging research. Your health matters, and having the right information can empower better health choices.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional for medical guidance and treatment options.
